IL10 and rheumatoid arthritis: Koffeman and collaborators (2009) [130] tested the oral administration of 25 mg dnaJP1 peptide in rheumatoid arthritis patients for 6 months reporting a reduction in TNF-alpha-producing T cells and an increase in IL-10-producing Treg cells associated with amelioration of disease.